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Diabetes is a well-known risk factor for invasive mucormycosis with rhinocerebral involvement. Acute necrosis of the maxilla is
seldom seen and extensive facial bone involvement is rare in patients with rhino-orbital-cerebral mucormycosis. An aggressive
surgical approach combined with antifungal therapy is usually necessary. In this report, we describe the successful, personalized
medical and surgical management of extensive periorbital mucormycosis in an elderly diabetic, HIV-negative woman. Mono- or
combination therapywith liposomal amphotericin B (L-AmB) and posaconazole (PSO) andwithheld debridement is discussed.The
role of aesthetic plastic surgery to preserve the patient’s physical appearance is also reported. Any diabetic patient with sinonasal
disease, regardless of their degree of metabolic control, is a candidate for prompt evaluation to rule out mucormycosis.Therapeutic
and surgical strategies and adjunctive treatments are essential for successful disease management.These interventions may include
combination therapy. Finally, a judiciousmultimodal treatment approach can improve appearance and optimize outcome in elderly
patients.
1. Introductions
Mucormycosis is an emerging angioinvasive infection caused
by the ubiquitous filamentous fungi belonging to the Muco-
rales order [1]. It is the third most common invasive fungal
infection after candidiasis and aspergillosis and it is a devas-
tating disease.
There has been a significant increase in incidence over
the last two decades due to predisposing factors such as
uncontrolled diabetes mellitus with or without ketoacidosis,
corticosteroid treatment, organ transplants, allogenic stem
cell transplants, neutropenia, trauma and burns, malignant
hematologic disorders, and deferoxamine therapy in patients
receiving hemodialysis [2, 3]. Diabetes was themost common
risk factor in several case series involving immunocompetent
patients [3, 4].Mucormycosis can occur in six different forms:
rhinocerebral, pulmonary, cutaneous, gastrointestinal, dis-
seminated, and uncommon presentation; the most frequent
sites of infection are pulmonary, rhinocerebral, cutaneous,
and disseminated [2]. This fungal infection is characterized
by a rapid progression to disseminated infection and a high
mortality rate, which is why early diagnosis and timely
intervention lead to a better outcome [2, 4, 5]. Although
considerable progress has been made using a multimodal
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approach to treating invasive mucormycosis, a number of
clinical issues still need to be resolved and therapeutic
outcome remains far below our expectations in many specific
areas.
Recently, ESCMID and ECMM joint clinical guidelines
pointed out that no clinical trials have been conducted
to evaluate the timing of fever-driven treatment against
mucormycosis [5]. Different studies in murine models and
in vitro have explored the efficacy of combination therapy
against members of the Mucorales order [6, 7].
Currently, novel regimens for the treatment of mucormy-
cosis include a combination of lipid-based amphotericin
plus either an echinocandin or itraconazole or both [7–9].
Although encouraging, recent guidelines stipulate that there
is still a lack of sufficient data to support a recommenda-
tion for combination therapy as the first-line treatment for
mucormycosis [5, 10].
In this report, we describe the successful, personal-
ized medical and surgical treatment of extensive periorbital
mucormycosis complicated by internal carotid thrombosis
in an elderly woman. Monotherapy with liposomal ampho-
tericin B (L-AmB) or posaconazole (PSO) and combination
of antifungal therapeutic strategies are discussed.
2. Case Presentation
In May 2013, a 72-year-old HIV-negative woman of Italian
origin and nationality was admitted to the plastic surgery unit
of the “P. Giaccone” Teaching Hospital in Palermo, Italy, with
extensive necrosis on the right side of her face.
The patient had a past medical history of hypertension,
chronic obstructive pulmonary disease (COPD), type 2 dia-
betes mellitus (DM), and a recent amaurosis fugax episode.
Home medications included atorvastatin 80mg daily,
furosemide 40mg daily, antiplatelet therapy with aspirin
(325mg daily), metformin 500mg twice/day, and irregular
treatment with fluticasone propionate plus salmeterol by
nebulizer.
The disorder started with symptoms consistent with
sinusitis; sinus pain, drainage, and soft tissue swelling were
reported over a period of 7 days.
When she was admitted to the Emergency Department
of the Paolo Giaccone University Hospital, she had been
suffering from severe headaches, facial numbness, and blurry
vision for 20 hours. Vital signs on admission were as follows:
temperature 36.5∘C, blood pressure 140/75mmHg, pulse
95 beats/min, respiratory rate 26 breaths/min, and oxygen
saturation 92% on room air.
Relevant laboratory values on admission were as fol-
lows: leucocytosis with 14.600 leucocytes with prevalence
of segmented elements (83%), glucose 220mg/dL, blood
urea nitrogen 76mg/dL, creatinine 2mg/dL, and creatinine
clearance (CrCl) 30mL/min.
CT images (Figures 1(a) and 1(b)) showed spreading cel-
lulitis on the right side of the face and cervicofacial areas with
loss of nasobuccal substance and lytic-type osteostructural
alteration on the right side of the hard palate with interrup-
tion of the cortical contour and, in part, of the alveolar process
of the jaw in the first sextant; magnetic resonance imaging
(Figures 1(c) and 1(d)) showed meningeal involvement and
localizations in the cerebral parenchyma and aqueduct of
Sylvius; a large amount of phlogistic tissue fills the Meckel’s
cavity and engulfs the intracavernous branches of the internal
carotid artery.
The patient underwent nasal endoscopy and a biopsy
was performed to remove tissue from the sites of infection
for examination. Histopathology tests showed fragments
of necrotic connective tissue associated with spores and
stubby and broad hyphae. They were irregularly shaped,
in many cases, with nondichotomous right-angle branch-
ing. They were more evident by hematoxylin-eosin staining
(H-E) Figure 2(a) than by PAS Figure 2(b). Gomori silver
methenamine (GMS) staining was also positive (Figures 2(c)
and 2(d)). These findings were in keeping with the diagnosis
of invasive mucormycosis.
Culture of a small fragment of a biopsy specimen onto
Sabouraud dextrose agar showed vigorous growth of colonies
that were consistent with “Mucorales” on the basis of both
gross colony morphology (floccose or “woolly”) and micro-
scopic features of slide culture (aseptate hyaline hyphae and
sporangium morphology: globose and deliquescent). The
isolate was not speciated andmolecular identificationwas not
performed.
Antimicrobial susceptibility testing (AST)was performed
using brothmicrodilution as described in the NCCLSM38-A
document [11] and as previously reported [12].
Amphotericin B (AMB) showed a MIC < 1 𝜇g/mL.
On the second day of hospitalization, the woman’s clinical
condition precluded surgical debridement of infected tissues
(exacerbations of COPD) and hyperbaric oxygen (catarrhal
otitis media); therefore monotherapy with parenteral liposo-
mal amphotericin B (L-AmB) at a dose of 3mg/kg/day was
started.
Figure 3(a) shows the patient’s lesions in the first preop-
erative period.
No improvement was observed after 3 weeks of antifungal
monotherapy; therefore combination therapy of posacona-
zole (400mg twice daily) plus L-AmBat the above-mentioned
dosage was started.
During hospitalization, the patient’s glucose levels were
restored to normal and kept in the normal range by switching
from oral medication to injected insulin.
After two weeks of combined antifungal treatment, there
was a general improvement in the patient’s state of health;
therefore an aggressive surgical debridement with orbital
exenteration was performed. This was followed by Mustarde`
flap reconstruction of residual substance in the maxillary
zygomatic region and local flap reconstruction on the upper
lip.
Two surgical specimens were sent to the pathology
laboratory, onemeasuring about 5 cm from the hemi face and
the other measuring 1.5 cm in diameter taken from the right
orbital cavity after the eye had been removed. Histological
examination showed necrotic tissue with fungal spores and
hyphae once again consistent with mucormycosis (data not
shown).
However, cultures of surgical specimens were negative.
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Figure 1: Base (axial plane) CT image shows the presence of a soft tissue density mass in the right sphenoid sinus, occluding the sinus
lumen and the spheno-ethmoid osteum also osteostructural alterations, mainly lytic, of the lateral sinus wall and in part of the large sphenoid
wing (a); base (coronal plane) CT image with MIP (maximum intensity project) reconstruction shows lytic osteostructural alteration of the
right side of the hard palate, with interruption of the cortical contour and, in part, of the alveolar process of the jaw in the first sextant (b);
axial T1-weighted MRI image after mdc administration shows meningeal enhancement in the right temporal lobe. Also enhancement of the
temporiun on the right side and the Sylvian aqueduct indicating transcompartment fungal infection involvement (c); coronal T1-weighted
MRI image after administration of mdc shows a large amount of phlogistic tissue, intensely and homogenously enhanced after mdc, which
fills the Meckel’s cavity and engulfs the intracavernous branches of the internal carotid artery in the absence of perceptible ischaemic lesions
of the brain parenchyma (d).
During hospitalization, the patient refused further surgi-
cal treatment, such as a neurosurgical procedure or endovas-
cular intervention.
Combination antifungal therapy was continued in the
same dose during the intraoperative phase and postsurgery
hospitalization, for a total of 24 days. The patient’s renal
function, liver function, and blood counts were closely
monitored; mean value of CrCl during hospitalization was
33 ± 4mL/min.
As a result of her optimal response to combined anti-
fungal therapy and good outcome after surgery, the patient
was discharged. Considering the extent of the lesions and the
patient’s underlying condition which precluded hyperbaric
oxygen treatment, prolonged combination antifungal therapy
was considered essential and an outpatient treatment regimen
was prescribed. Nevertheless, despite our concerns for her
health, she did not consent to intravenous antifungal treat-
ment with amphotericin B.
Therefore, the patient was discharged to continue
monotherapy with posaconazole at home for another 5
weeks. Posaconazole treatment was well tolerated and no
adverse effects were detected during the 60 days that the
drug was used in combination or in second-line therapy.
After discharge, the patient returned to the plastic surgery
clinic to have the surgical wound checked and the dressing
changed (Figure 3(b)).
Meanwhile, the patient appeared to be in good health and
wound biopsy specimens were negative for yeast infection.
At a recent follow-up examination a year after the dis-
charge, the patient did not show any symptoms of recurrent
disease.
3. Discussion
Treatment of rhinocerebral mucormycosis requires a multi-
faceted approach which includes antifungal agents, surgical
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Figure 2: Spores and broad, stubby, irregularly-shaped hyphae, in many cases with nondichotomous right-angle branching; (a) hematoxylin-
eosin staining, (b) PAS staining, and (c)-(d) Gomori silver methenamine staining; original magnification = 400x.
debridement, and correction of the underlying disease which
predisposes the individual to infection.
However, possible long-term complications such as loss
of oral and visual function, disfigurement, diminished quality
of life, and psychosocial consequences, together with their
impact on survival, force us to continue to redefine manage-
ment strategies for mucormycosis.
There are still a number of controversial issues regarding
both surgical and medical interventions.
Although early and extensive surgical debridement
appears to enhance survival [13], delayed and less aggressive
surgical interventions have also been reported [14].
In the case described here, our medical and surgical
approach was influenced by the patient’s clinical conditions.
In fact, debridement was withheld for 21 days and the patient
was given less than the recommended dose of L-AmB [5,
10]. Although high doses of L-AmB (7–10mg/kg/day) are
recommended [5, 10] for invasive mucormycosis and there is
no need to reduce the dose in patients with renal disease, we
decided to take into account the potential nephrotoxic effects
of L-AmB in older patients [15] and we prescribed a dose of
3mg/kg/daily for the whole course of treatment.
Moreover, our patient showed poor compliance with
intravenous medication and she refused further surgical
treatment, such as a neurosurgical procedure or endovascular
intervention. Although this precluded a multidisciplinary
approach, she did however consent to plastic surgery. This
decision was perhaps dictated by her fear of isolation and of
people’s reactions to her appearance. Moreover, the patient
was elderly and it was more important for her not to appear
as a “monster” than to extend her life.
After discharge, our patient refused intravenous treat-
ment and was therefore prescribed monotherapy with
posaconazole. ESCMID and ECMM guidelines recommend
posaconazole prophylaxis for mucormycosis and for salvage
treatment in patients resistant to other antifungal agents
used in previous treatments [5]. In this regard, our patient’s
favorable outcome was consistent with other published cases
in which the drug was frequently and successfully used in
combination or second-line therapy [16].
We added posaconazole to the L-AmB treatment regimen
before and after the patient’s surgical debridement. Single
case reports or case series available in the literature have
demonstrated the efficacy of a combination of posaconazole
plus L-AmB [17, 18]. James J. Mezhir reported that patients
with invasive mucormycosis were successfully treated with a
combination antifungal therapy of posaconazole plus L-AmB
without the need for surgical debridement [19].
Case Reports in Medicine 5
(a) (b)
Figure 3: Patient on admission (a) and after treatment (b).
Another potential endpoint for clinical studies that needs
to be spotlighted is the duration and dosage of antifungal
therapy using single-drug or combination strategies. Our
patient received antifungal drug medication for about 80
days. Although there are no exact indications regarding
the duration of treatment for rhinocerebral mucormycosis,
we believe that, in our patient’s case, prolonged antifungal
therapy was an important factor for survival.
Moreover, our patient took atorvastatin which, like other
statins, has shown activity against Mucorales and displayed a
synergistic effect when combined with azole [5].
Infected tissue biopsy is of fundamental importance
in mucormycosis diagnosis, as it can reveal the distinc-
tive hyphae characteristics (broad, ribbon-like, irregularly-
shaped, coenocytic, or sparsely septate, in many cases with
nondichotomous and right-angle branching) which are sug-
gestive of disease.
Nevertheless, culture often yields no growth and histo-
pathological identification of an organism which is struc-
turally identical to Mucorales is frequently the only evidence
of infection [20].
Although our patient’s underlying condition precluded
hyperbaric oxygen (HOB), it is considered a potentially
significant adjunctive treatment for invasive fungal infections
[5, 12, 21]. There is insufficient evidence to determine its
usefulness as a standard of care in these infections, but it may
be warranted in patients who appear to be deteriorating, in
spite of maximal surgical and medical therapy [5, 13].
Despite the emergence of new antifungal agents, mucor-
mycosis has an exceedingly high mortality rate; therefore
improving host response to infection appears to be a crit-
ical prognostic factor. Our case suggests that advanced
age probably contributes to a weaker immune response to
filamentous fungi such as zygomycetes due to changes in
T cell responses [22]. The precariousness of the situation is
accentuated by underlying conditions or comorbidities such
as cardiovascular disease or COPD in the elderly population
[23].
Finally, as this case report illustrates, medical and surgical
treatment of extensive rhinocerebral mucormycosis can be
successful [24], but the importance of long-term follow-up
and the potential for disease recrudescence must be taken
into account.
4. Conclusions
In conclusion, two interesting findings emerge from this
case report. Firstly, a long- term, multimodal treatment
approach consisting in combined antifungal drug therapy
(posaconazole + liposomial amphotericin B) and timely sur-
gical debridement can lead to an improvement in appearance
and in long-term outcome.
Secondly, our case report highlights the complex nature
of invasive fungal disease management in patients affected by
multiple concurrent chronic conditions, as is often the case in
elderly patients.
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